

Index

- ABIN-1 132
- acute-phase proteins 10
- adalimumab 4
- adeno-associated virus (AAV) 126, 127, 133, 134
- adenovirus 126, 127, 130, 131
- adjuvant-induced arthritis (AA) 1
- alkaline phosphatase, secreted heat-stable (Se AP) 149
- alpha-1-acid glycoprotein 10
- angiogenesis 86
- angiogenic response 90
- angiopoietin 134
- animal experimentation guidelines 188
- Animal Welfare Act 194
- Animals (Scientific Procedures) Act 1986 (ASPA) 178
- ankle swelling 9
- anti-CCP antibodies 6
- anti-collagen type II IgG antibodies 6
- antisense RNA 127
- arginase I 93, 94
- arthritis, chronic, pathogenesis of 35
- arthritis models 1, 35, 58, 128, 130, 132, 134
- asthma and airway hyperreactivity (AHR) 132–134
- asthma models 132, 134
- autoantibodies 6
- autoimmune cartilage and bone destruction 36
- autoimmune disorders 146
- B cell B29 11
- B cells 6
- bacterial artificial chromosomes (BACs) 141
- basic policies on animal experimentation as quasi-regulations, animal experimentation guidelines 188
- body weight loss 18
- bone destruction 35, 36
- bone formation 7
- bone pathology 15
- bone roughness 15
- bone volume 15
- bone-associated markers 11
- cancer, nanoparticles in 165, 166
- cantilevers 159, 160
- cartilage 2, 128, 130
- cartilage and bone markers 2
- cartilage destruction 35, 36, 55, 57, 128, 132
- cartilage pathology 13
- cartilage-associated oligomeric matrix protein (COMP) 13
- cathepsin K 11
- CC-chemokine receptor (CCR) 86
- CCL2 91
- CD4 11
- CD11b 11
- cell therapy approaches 110
- cell transplantation 116
- cell-cell fusion 114
- Certificate of Designation 178

- chemo-attractive mechanisms 116
- chemokines 84, 88, 91
- chitin 69
- chondrocytes 69, 128, 130
- chondroitin 69, 70
- chorioallantoic membrane (CAM) 87
- chromodacryorrhea 18
- chronic inflammation and cancer 83, 84, 86
- collagen emulsion, preparation of 20
- collagen type I fragments (Rat-LapsTM) 15
- collagen type II fragments (CartilapsTM) 13
- collagen-induced arthritis (CIA) 1, 36, 130, 134
- complete Freund's adjuvant (CFA) 1
- compound testing 17
- cornea 88, 89, 92
- corticosteroids 2
 - steroids 1
 - prednisone 2
- Crohn's disease 147
- CRP 11
- CTLA4-Ig 5
- CXCL8 91
- cyclooxygenase-2 (COX-2) 1, 11, 87, 93
- cyclosporine A 1, 4
- cytokines 7, 12, 47, 84, 85, 88, 90, 93

- dendrimers 157, 163
- detailed guidelines as a vital reference,
 - formulated by the SCJ 189
- disease-modifying antirheumatic drug (DMARD) 3
- DNA damage, initiation by inflammation 84
- drug delivery, liposomal formulations 166
- Duchenne muscular dystrophy (DMD) 104
- dystrophy and inflammation 107

- endothelial cell activation 148
- enforced self-regulation 190
- enhanced green fluorescent protein (EGFP) 146, 148
- eosinophils 92–94
- erythrocyte sedimentation rate (ESR) 10

- E-selectin, reporter mouse 148
- etanercept 4

- fibrin 7
- flare, arthritic 9
- FTY720 147

- gadofullerenes 160
- gene expression 2, 11, 12
- gene targeting,
 - BAC 141
 - conditional 141
 - homologous recombination 141
 - inducible 142
- gene transfer 125, 126
- gene transfer, *in vivo* 125
- gene transfer, somatic 125, 126
- gene-targeted mice 85, 92
- genetic predisposition 1
- GM-CSF 133
- Good Laboratory Practices 198, 199
- graft vessel disease (GVD) 148
- granulocytes 90, 93, 94
- granuloma 89
- growth factor 70, 84, 116
- Guide for the Care and Use of Laboratory Animals 197, 198

- haptoglobin 11
- heat shock protein 6
- herpes simplex virus 126, 127
- human placental alkaline phosphatase, secreted
 - heat-stable (SeAP) 149
- humane treatment of animals 190

- ibuprofen 2, 3
- ICAM 147
- IFN- γ 11, 132
- IL-1 1, 71, 75, 132
- IL-1 β 11
- IL-1R antagonist 7, 130
- IL-4 134

- IL-4, reporter mouse 148
IL-4Ra 134
IL-5 11
IL-6 11
IL-8 (CXCL8) 91
IL-10 11, 133
IL-12 133
IL-13 134
IL-18 132, 133
imaging 149, 157, 169
immune suppression 5, 84, 92
in vivo imaging 149
indoleamine 2,3-dioxygenase (IDO) 93, 94
inducible transgenic systems 142
inflammation in the pathogenesis of dystrophy 107
inflammation, nanoparticles in 165
infliximab 4
innate immunity 83, 84, 90
iNOS 11
Institutional Animal Care and Use Committee (IACUC) 194, 195
institutional responsibilities for conducting animal experiments 188
insulin-like growth factor (IGF-1) 110, 128
insulin-like growth factor 1 (mIGF-1), locally acting isoform 116
interferon-gamma 11, 132
interleukin-1 receptor antagonist (IL-1Ra) 7, 130
invertebrate 90
iron oxide nanoparticles, paramagnetic 162
- joint destruction 35
- knockout mouse 125, 126
- laboratory animals, guide for the care and use 197, 198
leflunomide 3
lentivirus 126, 127, 129
Lewis rats 9
lipopolysaccharide (LPS) 85, 88
- liposomes 157, 166
liposomal formulations for drug delivery 166–168
loxP 142, 144, 145
luciferase 149
lymph node 11
- macrophages 7, 90, 92, 94
mast cells 92
Matrigel 88, 89
matrix metalloproteases (MMPs) 85
mdx mouse strain 106
mesoangioblasts 115
methotrexate 1, 4
MHC class II alleles 5
micro-computed tomography (μ CT) 15
model validation 68
modulation of the inflammatory reaction 110
molecular imaging 169
molecular targets 68
monoarticular 100P model 20
monocyte chemoattractant protein 1 (MCP-1) 91
mRNA expression 11
muscle damage 105
muscle regeneration 109
muscular dystrophies 103
 Duchenne muscular dystrophy (DMD) 104
myeloid lineage cells 7
myoblast cell therapy 110
myonecrosis 106
- nano self-assembling systems 158
nanoarrays 165
nanomedicine 156
nanoparticles 157, 162, 165, 166
nanopore 158
nanoscale probes 156
nanoscale structures 157
nanosomes 163
nanostructures 157, 158
nanosystems 157, 158, 165

- nanotechnology 155
- nanotools 157
- nanotubes 160
- naproxen 2, 3
- neutrophils 7, 91, 92
- neutrophil counts 9
- nonsteroidal anti-inflammatory drugs (NSAIDs)
 - 1, 2
- nuclear factor-kappa B (NF- κ B) 132
- NF- κ B-induced inflammatory cytokines 11

- oncostatin M 132
- osteoarthritis, therapeutic agents (table) 69–75
- osteoarthritis animal models,
 - anterior cruciate ligament (ACL) 66
 - dog 66, 67, 70–75
 - guinea pig 66, 67, 69, 70, 73, 75
 - hamster 66, 69, 73
 - induced 66, 67
 - meniscectomy 66
 - mouse 67, 70, 74, 75
 - rabbit 66, 67, 69–75
 - rat 66, 67, 70, 72–74
 - spontaneous 66, 67
 - transgenic 66
- osteoclasts 7
- oxidative stress 93
- oxygen metabolites 7

- pannus tissue 7
- paramagnetic iron oxide nanoparticles 162
- peptidoglycan and polysaccharide (PG-PS) 2
- PG-PS 100P 5, 20
- periosteal bone formation 7
- persistence of inflammation 105
- Personal Licence 178, 182
- pharmacokinetic (PK) analysis 17
- plasma/serum and tissue cytokine levels 12
- plasmid DNA 127, 128
- plethysmometer 15
- polymersomes 163
- prednisone 2

- 3R principle, legal standing of 187
- progenitor cell 117
- Project Licence 178, 180–182
- pronuclear microinjection 140
- prophylactic treatments 2
- proteases 7
- Public Health Service Policy 196

- quantum dots 161

- 3R principle 187
- RANKL 11
- recombinase Cre/loxP 142
- recombinase FLP/FRT 142
- recombinase-mediated cassette exchange 143
- recruitment of BM cells 116
- regulatory T cells (T regs) 93, 94
- retrovirus 126, 127, 129
- rheumatoid arthritis 1, 35
- rheumatoid factor 6
- ribozymes 127
- RNA interference 145
- RNAi, inhibitory RNA 127

- S1P1 147
- sarcoglycan-null mutant mice 107
- sarcoglycanopathies 104
- satellite cells 109
- scientific rationality of *in vivo* research 190
- secreted heat-stable alkaline phosphatase (SeAP)
 - 149
- self regulation, enforced 190
- self-assembling systems 158
- serum acute-phase proteins 2
- serum fibrinogen levels 9
- short hairpin RNAs (shRNAs) 145
- side population (SP) 113
- signal transducer and activator of transcription 4 (STAT4) 133
- specific immunity 83
- stem cells 112
 - embryonic stem cells (ES) 111

- hematopoietic stem cells (HSC) 111
 - plasticity of 113
- steroids 1
- streptococcal cell wall-induced arthritis (SCW) 1
- synovial cells 130
- synovial fluid 7, 67
- synoviocyte 7
- synovium 7
- systemic 10S model 20
- T cells 4, 93, 94
 - T cell response 5
 - regulatory T cells (T regs) 93, 94
- TGF- β 11, 85
- therapeutic agents, osteoarthritis (table) 69–75
 - ascorbic acid 70
 - bisphosphonates 72
 - calcitonin 71
 - chitin 69
 - chondroitin 69, 70
 - collagen 70
 - estrogen related 70
 - exercise 69
 - glucosamine 69, 70
 - growth factors 70
 - hyaluronan (HA) 69
 - interleukin-1 related 71, 75
 - manganese 70
 - matrixmetalloproteinase inhibitors 73, 74
 - nitric oxide inhibitors 74
 - nonsteroidal antiinflammatories 72, 73
 - selenium 70
- therapeutic dosing regimes 2
- tissue regeneration/repair 103
- TNF- α 1, 11, 132, 147
- transdifferentiation of stem cells 112
- transforming growth factor-beta 1 (TGF- β 1) 11, 85
- transgenic mouse 85, 125, 126
- TRAP 11
- tumor xenograft 90
- type II collagen 18
- vascular endothelial growth factor (VEGF) 87, 90
- wound healing 90

The PIR-Series

Progress in Inflammation Research

Homepage: <http://www.birkhauser.ch>

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:

T Cells in Arthritis, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998
Medicinal Fatty Acids, J. Kremer (Editor), 1998
Inducible Enzymes in the Inflammatory Response,
D.A. Willoughby, A. Tomlinson (Editors), 1999
Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999
Fatty Acids and Inflammatory Skin Diseases, J.-M. Schröder (Editor), 1999
Immunomodulatory Agents from Plants, H. Wagner (Editor), 1999
Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999
In Vivo Models of Inflammation, D. Morgan, L. Marshall (Editors), 1999
Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999
Anti-Inflammatory Drugs in Asthma, A.P. Sampson, M.K. Church (Editors), 1999
Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
Vascular Adhesion Molecules and Inflammation, J.D. Pearson (Editor), 1999
Metalloproteinases as Targets for Anti-Inflammatory Drugs,
K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
Free Radicals and Inflammation, P.G. Winyard, D.R. Blake, C.H. Evans (Editors), 1999
Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000
New Cytokines as Potential Drugs, S. K. Narula, R. Coffmann (Editors), 2000
High Throughput Screening for Novel Anti-inflammatories, M. Kahn (Editor), 2000
Immunology and Drug Therapy of Atopic Skin Diseases,
C.A.F. Bruijnzeel-Komen, E.F. Knol (Editors), 2000
Novel Cytokine Inhibitors, G.A. Higgs, B. Henderson (Editors), 2000
Inflammatory Processes. Molecular Mechanisms and Therapeutic Opportunities,
L.G. Letts, D.W. Morgan (Editors), 2000

- Cellular Mechanisms in Airways Inflammation*, C. Page, K. Banner, D. Spina (Editors), 2000
- Inflammatory and Infectious Basis of Atherosclerosis*, J.L. Mehta (Editor), 2001
- Muscarinic Receptors in Airways Diseases*, J. Zaagsma, H. Meurs, A.F. Roffel (Editors), 2001
- TGF- β and Related Cytokines in Inflammation*, S.N. Breit, S. Wahl (Editors), 2001
- Nitric Oxide and Inflammation*, D. Salvemini, T.R. Billiar, Y. Vodovotz (Editors), 2001
- Neuroinflammatory Mechanisms in Alzheimer's Disease. Basic and Clinical Research*, J. Rogers (Editor), 2001
- Disease-modifying Therapy in Vasculitides*, C.G.M. Kallenberg, J.W. Cohen Tervaert (Editors), 2001
- Inflammation and Stroke*, G.Z. Feuerstein (Editor), 2001
- NMDA Antagonists as Potential Analgesic Drugs*, D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002
- Migraine: A Neuroinflammatory Disease?* E.L.H. Spierings, M. Sanchez del Rio (Editors), 2002
- Mechanisms and Mediators of Neuropathic pain*, A.B. Malmberg, S.R. Chaplan (Editors), 2002
- Bone Morphogenetic Proteins. From Laboratory to Clinical Practice*, S. Vukicevic, K.T. Sampath (Editors), 2002
- The Hereditary Basis of Allergic Diseases*, J. Holloway, S. Holgate (Editors), 2002
- Inflammation and Cardiac Diseases*, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003
- Mind over Matter – Regulation of Peripheral Inflammation by the CNS*, M. Schäfer, C. Stein (Editors), 2003
- Heat Shock Proteins and Inflammation*, W. van Eden (Editor), 2003
- Pharmacotherapy of Gastrointestinal Inflammation*, A. Guglietta (Editor), 2004
- Arachidonate Remodeling and Inflammation*, A.N. Fonteh, R.L. Wykle (Editors), 2004
- Recent Advances in Pathophysiology of COPD*, P.J. Barnes, T.T. Hansel (Editors), 2004
- Cytokines and Joint Injury*, W.B. van den Berg, P. Miossec (Editors), 2004
- Cancer and Inflammation*, D.W. Morgan, U. Forssmann, M.T. Nakada (Editors), 2004
- Bone Morphogenetic Proteins: Bone Regeneration and Beyond*, S. Vukicevic, K.T. Sampath (Editors), 2004
- Antibiotics as Anti-Inflammatory and Immunomodulatory Agents*, B.K. Rubin, J. Tamaoki (Editors), 2005
- Antirheumatic Therapy: Actions and Outcomes*, R.O. Day, D.E. Furst, P.L.C.M. van Riel, B. Bresnihan (Editors), 2005
- Regulatory T-Cells in Inflammation*, L. Taams, A.N. Akbar, M.H.M. Wauben (Editors), 2005
- Sodium Channels, Pain, and Analgesia*, K. Coward, M. Baker (Editors), 2005
- Turning up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation*, A.B. Malmberg, K.R. Bley (Editors), 2005
- The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer*, Z. Zukowska, G. Z. Feuerstein (Editors), 2005
- Toll-like Receptors in Inflammation*, L.A.J. O'Neill, E. Brint (Editors), 2005
- Complement and Kidney Disease*, P. F. Zipfel (Editor), 2006
- Chemokine Biology – Basic Research and Clinical Application, Volume 1: Immunobiology of Chemokines*, B. Moser, G. L. Letts, K. Neote (Editors), 2006
- The Hereditary Basis of Rheumatic Diseases*, R. Holmdahl (Editor), 2006
- Lymphocyte Trafficking in Health and Disease*, R. Badolato, S. Sozzani (Editors), 2006
- In Vivo Models of Inflammation*, 2nd Edition, Volume II, C.S. Stevenson, L.A. Marshall, D.W. Morgan (Editors), 2006